ProCE Banner Activity

Experts Discuss Claudin 18.2: A New Target for Precision Care of Gastric and Gastroesophageal Cancers

Podcast Episodes

In this podcast episode, experts Samuel Klempner, MD, and Gregory Botta, MD, PhD, discuss the rationale supporting claudin 18.2 as a therapeutic target and clinical considerations for related emerging therapies in the treatment of gastric and gastroesophageal cancers.

Released: March 28, 2023

Share

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from

Astellas

Bristol Myers Squibb

Faculty Disclosure

Gregory Botta, MD, PhD: consultant/advisor/speaker: Natera, TumorGen.

Samuel Klempner, MD: consultant/advisor/speaker: Amgen, Astellas, Exact Sciences, Merck, Mersana, Natera, Novartis, Sanofi-Aventis, Servier; stock/stock options: Nuvalent, Turning Point.